Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Common Equity (2016 - 2025)

Zevra Therapeutics' Common Equity history spans 11 years, with the latest figure at $154.7 million for Q4 2025.

  • For Q4 2025, Common Equity rose 289.9% year-over-year to $154.7 million; the TTM value through Dec 2025 reached $154.7 million, up 289.9%, while the annual FY2025 figure was $154.7 million, 289.9% up from the prior year.
  • Common Equity reached $154.7 million in Q4 2025 per ZVRA's latest filing, up from $133.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $154.7 million in Q4 2025 to a low of -$7.5 million in Q1 2022.
  • Average Common Equity over 5 years is $69.7 million, with a median of $61.7 million recorded in 2023.
  • Peak YoY movement for Common Equity: plummeted 108.94% in 2022, then skyrocketed 2050633.33% in 2023.
  • A 5-year view of Common Equity shows it stood at $101.7 million in 2021, then decreased by 26.11% to $75.1 million in 2022, then dropped by 17.65% to $61.9 million in 2023, then plummeted by 35.88% to $39.7 million in 2024, then skyrocketed by 289.9% to $154.7 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Common Equity are $154.7 million (Q4 2025), $133.2 million (Q3 2025), and $117.2 million (Q2 2025).